Ein Business-Meeting (Symbolbild).
Freitag, 09.09.2016 19:20 von | Aufrufe: 93

INVESTOR ALERT: Rosen Law Firm Reminds Tokai Pharmaceuticals, Inc. Investors of Important September 30 Deadline in Class Action - TKAI

Ein Business-Meeting (Symbolbild). © gilaxia / E+ / Getty Images

PR Newswire

NEW YORK, Sept. 9, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Tokai Pharmaceuticals, Inc. securities (NASDAQ: TKAI) from June 24, 2015 through July 25, 2016, both dates inclusive (the "Class Period") of the important September 30, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Tokai Pharmaceuticals investors under the federal securities laws.

Rosen Law Firm, P.A. Logo

To join the Tokai Pharmaceuticals class action, go to the firm's website at http://rosenlegal.com/cases-928.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for more information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) there were significant structural problems with the trial design for Tokai Pharmaceuticals' pivotal Phase 3 galeterone study, ARMOR3-SV; (2) in turn, ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; (3) consequently, commercialization of galeterone was less likely and/or imminent than Tokai Pharmaceuticals had led investors to believe; and (4) as a result, defendants' statements about Tokai Pharmaceuticals' business and operations were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm's website at http://rosenlegal.com/cases-928.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com. Attorney Advertising.  Prior results do not guarantee a similar outcome.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.


ARIVA.DE Börsen-Geflüster

Kurse

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY  10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com

Logo - http://photos.prnewswire.com/prnh/20160907/405060LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/investor-alert-rosen-law-firm-reminds-tokai-pharmaceuticals-inc-investors-of-important-september-30-deadline-in-class-action---tkai-300325588.html

SOURCE Rosen Law Firm, P.A.

Werbung

Mehr Nachrichten zur Tokai Pharmaceuticals Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News